newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

  • IGC Pharma, Inc. is evaluating potential civil remedies following a federal jury verdict in United States v. Andrew Left.
  • Andrew Left, founder of Citron Research, was convicted of one count of engaging in a securities fraud scheme and 12 counts of securities fraud.
  • The federal indictment identified IGC as a target of the alleged scheme, which included a short campaign executed in October 2018.
  • The Company is reviewing public records, the jury verdict, & SEC materials to determine if it has recoverable damages.
  • Potential damages under review include harm to market value, reputational damage, operational harm, & legal costs.
  • The indictment alleged that trading related to short campaigns targeting IGC generated over $3.8 million in profits for a hedge fund & over $1.1 million for Left.
  • In a separate settled SEC proceeding, Anson Advisors agreed to pay $2.25 million in civil penalties regarding profits from a short position related to an IGC tweet.
  • Any decision to pursue claims will be made by the Board of Directors based on counsel recommendations & in the best interests of shareholders.
  • IGC Pharma's primary operational focus remains advancing its Alzheimer's disease programs, specifically the Phase 2 CALMA clinical trial for IGC-AD1.